Nonsteroidal antiandrogens are generally used in conjunction with castration as combined @entity342 blockade. However, the changing profile of @entity1 with @entity263 has made monotherapy with a nonsteroidal antiandrogen an attractive alternative therapeutic approach, offering potential quality-of-life benefits over conventional treatment modalities. Of available antiandrogens, monotherapy with @entity12195 has been most extensively evaluated. Combined data from 2 studies at a median follow-up time of 6.3 years revealed no statistically significant difference in overall survival between @entity12195 150-mg monotherapy and castration in @entity1 with nonmetastatic locally advanced disease. In @entity1 with @entity3 , there was a statistically significant difference (6 weeks) in overall survival in favor of castration. @entity12195 monotherapy is associated with significant quality-of-life benefits (sexual interest and physical capacity), with preliminary data suggesting that the risk of @entity170 may also be reduced by @entity12195 150-mg monotherapy compared with castration. In general, @entity12195 is well tolerated, with a predictable adverse-effect profile. @entity5026 (40%) and @entity247 (49%) are the most common adverse events seen during monotherapy with this drug. In summary, the availability of @entity12195 150-mg monotherapy broadens treatment options for @entity1 with locally advanced @entity263 , offering a viable and attractive alternative to castration in this @entity1 population. Ongoing studies will determine the role of @entity12195 in the treatment of @entity66 .

Antiandrogen monotherapy: a new form of treatment for @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity12195 :: ('MESH:C053541', 'Chemical') :: ['Bicalutamide', 'bicalutamide'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity5026 :: ('MESH:D059373', 'Disease') :: ['Breast pain'] @entity247 :: ('MESH:D006177', 'Disease') :: ['gynecomastia'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
